InvestSMART

PYC Therapeutics Limited (ASX:PYC)

ALERT: Price-sensitive ASX Announcement for PYC
Current share price for PYC : $1.535 0.34 (28.45%)+
Announcement
Release
27 Oct 2025 9:31AM
Price at Release
$1.195
Full Release
download
Summary
PYC Therapeutics Limited, an RNA therapeutics company, reported significant progress in its drug development programs during Q3 2025, as outlined in their Appendix 4C cash flow report. The company has advanced four drug candidates targeting genetic diseases, with three programs in human trials. These include treatments for Polycystic Kidney Disease, Retinitis Pigmentosa type 11, Autosomal Dominant Optic Atrophy, and Phelan McDermid Syndrome, reflecting PYC's commitment to addressing severe unmet medical needs. The financial report reveals a net cash decrease due to substantial R&D investments, closing with $135,078k in cash and equivalents, with no current borrowings and an estimated 7.74 quarters of funding remaining. The company is also preparing for upcoming safety and efficacy data releases in 2025-2027, underscoring their strategic focus on advancing clinical trials and regulatory alignment.
Key Points
  • PYC Therapeutics is developing RNA therapeutics for genetic diseases.
  • Significant progress in drug development programs during Q3 2025.
  • Four drug candidates, three in human trials: PKD, RP11, ADOA, PMS.
  • Net cash decrease due to high R&D expenditure.
  • Cash and equivalents at quarter-end: $135,078k.
  • Estimated 7.74 quarters of funding available.
  • Preparing for human safety and efficacy data releases in 2025-2027.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.